HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

NCT05029973 PHASE2 UNKNOWN

To Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC) Combined With Sintilimab and Bevacizumab Biosimilar in the Treatment of Patients With Unresectable Hepatocellular Carcinoma.

Details

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	PHASE2
Status	UNKNOWN
Enrolment	30
Start date	Mon May 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Nov 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hepatocellular Carcinoma

Interventions

• HAIC
• Sintilimab
• Bevacizumab Biosimilar

Countries

China